

Name of the Issuer:		Metropolis Healthcare Limited		
1	Type of Issue (IPO / FPO)	IPO		
2	Issue Size (Rs. Million)*	12,042.88		
	- Fresh Issue Size (Rs. Millions)			
	- Offer for Sale Component (Rs. Millions)	12,042.88		
	Source: Final post issue report dated April 16, 2019			
3	Grade of issue along with name of the rating agency	Not Applicable		
	Name	Not Applicable		
	Grade	Not Applicable		
4	Subscription Level (Number of times)	3.68*		
	Source: Final post issue report dated April 16, 2019			
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
	Particulars	%		
	(i) allotment in the issue ⁽¹⁾	20.44%		
	(ii) at the end of 1st Quarter immediately after the listing ⁽²⁾	21.71%		
	(iii) at the end of 1st FY (March 31, 2020) ⁽²⁾	22.24%		
	(iv) at the end of 2nd FY (March 31, 2021) ⁽²⁾	42.97%		
	(v) at the end of 3rd FY (March 31, 2022)*	38.11%		
	* QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.			
	(1) Source: Basis of Allotment. Includes allotment to Anchor Investors			
	(2) Source: Stock Exchange Website			
6	Financials of the issuer			
		(In Rs. Millions)		
	Parameters	1st FY (March 31, 2020)	2nd FY (March 31, 2021)	3rd FY (March 31, 2022)*
	Income from operations	6,564.05	9,979.87	12283.36
	Net Profit for the period	1,275.52	1,833.49	2146.86
	Paid-up equity share capital	101.26	102.23	102.34
	Reserves excluding revaluation reserves	5,133.70	6,963.77	8759.63
	* Financials not available as reporting for the relevant fiscal year has not been completed.			
7	Trading Status in the scrip of the issuer			
	Company's Equity Shares shall be listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE"). The Shares have not been suspended or delisted.			
	Particulars	Status		
	(i) at the end of 1st FY (March 31, 2020)	Frequently Traded		
	(ii) at the end of 2nd FY (March 31, 2021)	Frequently Traded		
	(iii) at the end of 3rd FY (March 31, 2022)	Frequently Traded		
	*Trading status not disclosed as the relevant fiscal year has not been completed			
8	Change in Directors of issuer from the disclosures in the offer document			
	Particulars	Name of the Director	Appointed / Resigned	
	(i) at the end of 1st FY (March 31, 2020)	Mihir Jagdish Doshi	-	
	(ii) at the end of 2nd FY (March 31, 2021)	Anita Ramachandran	Appointed	
	(iii) at the end of 3rd FY (March 31, 2022)	Hemant Sachdev	Appointed	
	Source: Stock Exchange Filings			
	Changes in Directors not disclosed as the relevant fiscal year has not been completed			
9	Status of implementation of project/ commencement of commercial production			
	(i) as disclosed in the offer document	Not applicable		
	(ii) Actual implementation	Not applicable		
	(iii) Reasons for delay in implementation, if any	Not applicable		
10	Status of utilization of issue proceeds			
	(i) as disclosed in the offer document	Not Applicable		
	(ii) Actual utilization	Not Applicable		
	(iii) Reasons for deviation, if any	Not Applicable		

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds	
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Not Applicable
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.): 880
 Designated Stock Exchange: BSE
 Listing Date: 15-Apr-19

Price parameters	At close of listing day (April 15, 2019)	At close of 30th calendar day from listing day (May 14, 2019) ⁽¹⁾	At close of 90th calendar day from listing day (July 13, 2019) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2020) ⁽³⁾			As at the end of 2nd FY after the listing of the issue (March 31, 2021) ⁽³⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2022) ⁽³⁾⁽⁴⁾		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	959.55	912.85	1,067.45	1,288.25	2,110.00	904.85	2,241.05	2,344.95	1,150.00	2,036.70	3,473.60	1,861.40
BSE SENSEX	38,905.84	37,318.53	38,736.23	29,468.49	42,273.87	25,638.90	49,509.15	52,516.76	27,500.79	58,568.51	61,765.59	47,705.80
S&P BSE Healthcare	14,505.67	13,452.29	12,923.39	12,148.57	14,663.74	10,947.99	21,328.21	22,464.34	11,878.39	24,303.83	26,879.99	21,528.53

Note:
 (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
 (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
 (3) High and Low based on intra day prices
 (4) Pricing data not disclosed as the relevant fiscal year has not completed

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2020)	At the end of 2nd FY (March 31, 2021)	At the end of 3rd FY (March 31, 2022) ⁽²⁾
EPS	Issuer:			
	Consolidated (Basic)	20.61	25.25	35.79
	Peer Group:			
	Dr. Lal Pathlabs Limited	20.85	27.37	35.25
	Industry Avg:	20.85	27.37	35.25
P/E	Issuer:			
	Based on Consolidated Basic EPS	42.70	50.72	62.62
	Peer Group:			
	Dr. Lal Pathlabs Limited	50.57	51.12	76.63
	Industry Avg:	50.57	51.12	76.63
RoNW	Issuer:			
	Consolidated	24.66%	24.29%	25.89%
	Peer Group:			
	Dr. Lal Pathlabs Limited	21.61%	21.59%	23.24%
	Industry Avg:	21.61%	21.59%	23.24%
NAV per share	Issuer:			
	Consolidated	83.58	103.72	138.52
	Peer Group:			
	Dr. Lal Pathlabs Limited	96.93	126.47	153.10
	Industry Avg:	96.93	126.47	153.10

Notes:
 (1) Sourced from Prospectus dated April 8, 2019.
 (2) Information not provided as the relevant fiscal year has not completed
 Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:
 (i) EPS - Fully diluted EPS as reported by the Company in its Annual Report.
 (ii) P/E - Closing Price as of relevant fiscal year end / EPS
 (iii) RoNW - Net Profit After Tax / Closing networth (Share Capital + Reserves and Surplus - Miscellaneous expenses)
 (iv) NAV per share - Closing Networth / Shares Outstanding as of fiscal year end

14 Any other material information

Announcement	Date of disclosure to Designated Stock Exchange
In continuation to our intimation dated April 01, 2022 having Reference No. MHL/Sec&Legal/2022-23/01, we wish to inform that the pursuant to the ongoing voluntary liquidation process, the liquidator of Hitech, has transferred the entire business undertaking of Hitech to the Company on a going concern basis on and with effect from 4th June 2022.	4-Jun-22
Company has informed the Exchange about Board Meeting held on 24-May-2022 to consider financial statements for the period ended March 2022.	24-May-22
Company has informed the Exchange regarding Allotment of 128 Shares under ESOP scheme.	14-Apr-22
Board of Directors of Hitech in their Meeting dated April 1, 2022 and the Members of Hitech in their Extra Ordinary General meeting held at a shorter notice on April 1, 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process (subject to approval of the creditors of Hitech) and consequential appointment of the professional as required under the statute. Accordingly, subject to approval of the creditors of Hitech, the process shall be deemed to have been commenced from April 1, 2022. Pursuant to the voluntary liquidation, the entire business undertaking of Hitech, on a going concern basis, shall be distributed to the Company. Kindly take the above on record.	1-Apr-22

Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia:

- i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021.

11-Feb-22

- ii. Approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22.

Company has informed the Exchange regarding Allotment of 1626 Shares under ESOP scheme

5-Jan-22

Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2021 and took note of the Limited Review Report issued by the Statutory Auditors of the Company on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2021. This is to inform you that the Board of Directors of the Company at their meeting held today have inter-alia approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2021 and took note of the Limited Review Report issued by the Statutory Auditors of the Company on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2021.

10-Nov-21

Company has informed that in continuation to our earlier intimation dated October 15, 2021 having reference no. MHL/Sec&Legal/2021-22/49 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that Metropolis Healthcare Limited ("the Company") has completed the acquisition of 100% stake of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ("Hitech") along with its subsidiary Centralab Healthcare Services Private Limited ("Centralab") on October 22, 2021 for a cash consideration of Rs.636 Crores (Six Hundred and Thirty-Six Crores Only) as per the terms and conditions of the Share Purchase Agreement including amendments thereof entered between the Company and the sellers. Post completion of the aforesaid acquisition, "Hitech" and "Centralab" has become wholly-owned subsidiary and step down wholly owned subsidiary respectively of the Company.

22-Oct-21

Company has informed that CRISIL, a Credit Rating Agency has revised its outlook on the rating from 'CRISIL AA+Stable' to 'CRISIL AA+Positive' on the Non-Convertible Debentures and the long-term loan facility of the Company and has also reaffirmed its 'CRISIL A1+' rating to the short-term facility of the Company.

20-Oct-21

Company has informed the Exchange regarding allotment of 364 securities pursuant to ESOP/ESPS at its meeting held on October 11, 2021

11-Oct-21

Company has informed the Exchange regarding Allotment of 15800 Shares under ESOP scheme

6-Aug-21

Company has informed that the Board of Directors of the Company at their meeting have inter-alia:

1. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2021;

2. Took note of the recommendation of the Audit Committee and subject to requisite consents / approvals, approved the Scheme of merger by absorption of Bokal Gowlikar Metropolis Healthcare Private Limited and Desai Metropolis Health Services Private Limited and Dr. Patel Metropolis Healthcare Private Limited and Lab One Metropolis Healthcare Services Private Limited and Micron Metropolis Healthcare Private Limited and R. V. Metropolis Diagnostic & Health Care Center Private Limited and Raj Metropolis Healthcare Private Limited and Sudharma Metropolis Health Services Private Limited ("Transferor Companies") with the Company and their respective Shareholders ("Scheme") under the provisions of sections 230 to 232 of the Companies Act, 2013;

6-Aug-21

3. Approved fund raise of up to Rs. 15,000 million by way of private placement or preferential issue or public issue or through any other permissible mode and/or combination thereof, including by way of qualified institutions placement, in accordance with applicable laws and subject to appropriate sanctions, permission and approvals including shareholders' approval and statutory and regulatory approvals, as may be required;
4. Approved the Postal ballot Notice in terms of Section 110 of the Companies Act, 2013 read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 for seeking shareholders' approval;

5. Approved the acquisition of the balance Equity stake of 35% i.e. 10,50,000 Equity shares of Rs.10/- each in Metropolis Histopert Digital Services Private Limited ("Histopert") pursuant to a fresh valuation report issued by M/s. R.V. Shah & Associates, Chartered Accountants;

6. Approved the appointment of Ms. Simmi Singh Bisht having Membership Number ACS 23360 as the Company Secretary and Compliance Officer of the Company (designated as Head - Legal and Secretarial) with effect from August 6, 2021 and took note of the cessation of Mr. Danish Aliana as the Interim Compliance Officer of the Company with effect from August 6, 2021;

<p>Company has The Board of Directors of Metropolis Healthcare Ltd ("the Company") had approved the acquisition of Dr. Ganesan's Hitech Diagnostic Centre Private Limited and its subsidiary Centralab Healthcare Services Private Limited on 17th January 2021 in a combination of cash and equity shares deal. To achieve the closure of the transaction the Company took shareholder and other necessary approvals. However, through delays in the completion of the Sellers' obligations under the Share Purchase Agreement ("SPA"), the transaction as contemplated under the SPA was initiated but has not been wholly consummated till date. In the interim, the statutory approvals obtained by the Company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained.</p> <p>The Company, since the 3rd/4th week of April 2021, through various discussions and correspondences has been trying to conclude the said transaction with the Sellers under the SPA. A letter was also issued on 5th July 2021 to the Sellers asking them to fulfill their obligations under the SPA and communicate to the Company on the said transaction, failing which it will be considered as a confirmation by the Sellers of their intention to terminate the transaction without prejudicing the rights of the Company under the SPA. In the view of no communication from the Sellers to the letter issued on 5th July 2021, it can be assumed that the Sellers are not intending to close the transaction. The Company is presently evaluating its rights, and the various routes available for their enforcement, and will accordingly take appropriate actions on this matter</p>	10-Jul-21
<p>Company has informed the Exchange regarding Allotment of 25416 Shares under ESOP scheme</p>	8-Jul-21
<p>Company has informed the Exchange regarding Allotment of 12100 Shares under ESOP scheme</p>	27-May-21
<p>Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia:</p> <ol style="list-style-type: none"> 1. Approved the Standalone and Consolidated Financial Statements of the Company for the quarter and year ended March 31, 2021. <p>The Audited Standalone and Consolidated Financial Statements of the Company as approved together with the Auditor's Report thereon for the quarter and year ended March 31, 2021 are enclosed as Annexure 1.</p> <p>Further, pursuant to the provisions of Regulation 33 (3) (d) of the SEBI LODR, the declaration of Unmodified Opinion by the Managing Director of the Company, in respect of the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2021 is enclosed as Annexure 2. <ol style="list-style-type: none"> 2. Approved the appointment of Mr. Hemant Sachdev as an Additional Non-Executive NonIndependent Director of the Company, who shall hold office till the date of the forthcoming Annual General Meeting and shall continue to hold office thereafter, subject to the approval of the members of the Company at the forthcoming Annual General Meeting. <p>The details as required to be disclosed pursuant to Regulation 30 of the SEBI LODR read with SEBI Circular CIR/CFD/CMD/4/2015 are enclosed as Annexure 3. <ol style="list-style-type: none"> 3. Approved the re-constitution of the Risk Management Committee. The current and the earlier constitution of the Risk Management Committee is enclosed as Annexure 4. 4. Accepted and took on record the resignation of Ms. Poonam Tanwani from the post of Company Secretary and Compliance Officer of the Company with effect from close of business hours of May 31, 2021 and approved the appointment of Mr. Danish Allana, Associate Company Secretary (having membership no. A61517) as an Interim Compliance Officer of the Company with effect from June 1, 2021. </p></p>	27-May-21
<p>Company has informed the Exchange regarding a press release dated March 30, 2021, titled "Ameera Shah awarded EY Entrepreneur of the Year in life science"</p>	30-Mar-21
<p>We wish to inform you that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held today has:</p> <ol style="list-style-type: none"> 1. Approved the allotment of 10,000 (Ten Thousand) Equity Shares of Rs. 2/- (Rupees Two Only) each at an Exercise price of Rs.705.77 (Rupees Seven Hundred and Five and Seventy-Seven Paise Only) per Equity Share aggregating to Rs.70,57,700/- (Rupees Seventy Lakh Five Seven Thousand Seven Hundred Only) to the eligible employees of the Company who have exercised their stock options pursuant to the Metropolis Employees Stock Option Scheme-2015 ("MESOS 2015"). The said shares shall rank pari passu in all respects with the existing Equity shares of the Company. Consequent, upon the allotment of the aforesaid shares, the paid-up Equity Share Capital of the Company shall stand increased from Rs.10,22,13,626 consisting of 5,11,06,813 Equity shares of Rs. 2/- each to Rs. 10,22,33,626 consisting of 5,11,16,813 Equity Shares of Rs. 2/- each. 2. Approved the grant of 4,550 Restricted Stock Units pursuant to the Metropolis - Restrictive Stock Unit Plan - 2020 (MH-L - RSU Plan 2020) to the eligible employees of the Company / Subsidiary(ies). 	10-Feb-21
<p>Board of Directors of the Company at their meeting held today have inter-alia:</p> <p>Approved the re-appointment of Ms. Ameera Sushil Shah as the Managing Director, for a period of five years with effect from March 18, 2021, as per the recommendation of the Nomination and Remuneration Committee, subject to approval of members of the Company at the ensuing Annual General Meeting.</p> <p>Approved and declared payment of Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per equity share on the Face Value Rs. 2 (Rupees Two only) each for the financial year 2020-2021. The interim dividend will be paid to the members whose names appear in the Register of Members / Register of beneficiaries as on the 'Record Date' i.e. February 19, 2021. The Interim Dividend will be paid to the shareholders within 30 days of declaration.</p> <p>Approved the change in constitution of the Nomination and Remuneration Committee of the Company with effect from February 10, 2021.</p>	10-Feb-21

Metropolis Healthcare Ltd., India's leading diagnostic service provider, today announced the launch of a new laboratory in Kochi, Kerala. The 5,200 sq. ft. laboratory has the capability to conduct more than 30,000 sample testing per month including pathology tests ranging from basic pathology tests to high-end molecular diagnostic tests.	5-Feb-21
We wish to inform you about the Press Release on the topic: 'Metropolis Healthcare to acquire Hitech Diagnostic Centre to strengthen its leadership position in South India'	17-Jan-21
Board of Directors of Metropolis Healthcare Limited (the Company) at their meeting held today, have inter-alia considered and approved: 1. Increase in limits available with the Company to provide loan, guarantee to any person or Body Corporate or make investment in any Body Corporate under Section 186 of the Companies Act, 2013 from Rs.500 Crores to Rs.1200 Crores, subject to the approval of the shareholders. 2. Acquisition of entire 100% stake in Dr. Ganesan's Hitech Diagnostic Centre Private Limited and its subsidiary (Hitech) from its existing promoters / shareholders for a consideration to be discharged partly by Cash and partly by issuance of equity shares of the Company as per the details mentioned in the Annexures. 3. Issuance of up to 495000 equity shares of face value Rs. 2/- each fully paid up of the Company at a price to be arrived on the Relevant Date, as per Regulation 164 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2019, to the promoters / shareholders of Hitech on a Preferential basis for consideration other than cash subject to approval of the shareholders.	17-Jan-21
We wish to inform you that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held today has: 1. Approved the allotment of 1,77,887 (One Lakh Seventy Seven Thousand Eight Hundred and Eighty Seven) Equity Shares of Rs. 2/- (Rupees Two Only) each at an exercise price of Rs. 705.77 (Rupees Seven Hundred and Five and Seventy-Seven Paise Only) per Equity Share aggregating to Rs.12,55,47,310/- (Rupees Twelve Crores Fifty Five Lakhs Forty Seven Thousand Three Hundred and Ten Only) to the eligible employees of the Company who have exercised their stock options pursuant to the Metropolis Employees Stock Option Scheme-2015 ("MESOS 2015"). The said shares shall rank pari passu in all respects with the existing Equity shares of the Company. Consequently, upon the allotment of the aforesaid shares, the paid-up Equity Share Capital of the Company shall stand increased from Rs. 10,18,57,852 consisting of 5,09,28,926 Equity Shares of Rs. 2/- each to Rs.10,22,13,626 consisting of 5,11,06,813 Equity shares of Rs. 2/- each. 2. Approved the grant of 22,750 Restricted Stock Units pursuant to the Metropolis - Restrictive Stock Unit Plan - 2020 (MHL - RSU Plan 2020) to the eligible employees of the Company / Subsidiary(ies).	12-Nov-20
We wish to inform you that the Company has successfully acquired the balance stake of 49% in Raj Metropolis Healthcare Private Limited. Thus, Raj Metropolis has now become a wholly-owned subsidiary of the Company.	5-Nov-20
We wish to inform you that CRISIL, a Credit Rating Agency has reaffirmed its 'CRISIL AA-/Stable' rating on the Non-Convertible Debentures and the long-term loan facility of the Company and has also reassigned its 'CRISIL A1+' rating to the short-term bank facility of the Company. Further, please note that the Company has neither issued the Non-Convertible Debentures nor availed the long-term or short-term bank facility as aforesaid till date. The rating rationale dated September 30, 2020 received from CRISIL on October 1, 2020 and accepted by the Company	1-Oct-20
Company has informed that the Board of Directors of the Company at their meeting held today through video conferencing have inter-alia:	
1. Approved the acquisition of balance Equity stake of 35% i.e. 10,50,000 Equity shares of Rs.10/- each in Metropolis Histopert Digital Services Private Limited ('Histopert').	11-Aug-20
2. Approved the acquisition of balance Equity stake of 49% i.e. 8,894 Equity shares of Rs.10/- each in Raj Metropolis Healthcare Private Limited ('Raj Metropolis').	
Company has informed that pursuant to circular resolution passed by the Board of Directors of the Company on May 14, 2020 upon a recommendation by the Nomination and Remuneration Committee, Ms. Anila Ramachandran (DIN: 00118188) has been appointed as an Additional Director (Non-Executive Independent) under the Category of Women Independent Director with effect from May 14, 2020 and she shall hold the office upto the date of ensuing Annual General Meeting; and upon regularisation of her appointment as an Independent Director by the members in the ensuing Annual General Meeting, she shall continue to hold the office as Independent Director for a period of 5 years commencing from the 14th May, 2020.	15-May-20
Company has informed that Mr. Mihir Jagdish Doshi (DIN:01283331) has resigned as a Non-Executive-Non-Independent Director on the Board of the Company with immediate effect from April 30, 2020 due to his pre-occupations which is duly accepted by the Company on April 30, 2020	30-Apr-20
Company has informed that Ms. Poonam Tanwani bearing Membership Number A19182, on recommendation of Nomination and Remuneration Committee and approval of the Board of Directors of the Company in their meeting held on February 06, 2020, has been appointed as Company Secretary and Compliance Officer of the Company with effect from February 10, 2020, pursuant to Section 203 of Companies Act, 2013 and Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015	10-Feb-20
Company has informed that Board of Directors (the "Board") at its meeting held today i.e. February 06, 2020, inter-alia considered and approved the payment of Interim Dividend of Rs.8/- (Rupees Eight Only) per equity share of the face value of Rs. 2/- (Rupee Two Only) each for the financial year 2019-20. The interim dividend will be paid to the members whose names appears in the Register of Members / Register of beneficiaries as on the 'Record Date' i.e. Saturday, February 15, 2020. The Interim Dividend will be paid to the entitled shareholders within 30 days of declaration.	6-Feb-20

Company has informed that the Board of Directors at their meeting held on January 15, 2020 have approved the acquisition of Shradha Diagnostic Centre (I) Private Limited and the Share Purchase and Shareholders' Agreement is executed today i.e. January 16, 2020.

16-Jan-20

Company has informed that it has initiated steps for appointment of a Company Secretary of the Company. In the interim period Company has appointed Ms. Varsha Hardasani, an Associate Company Secretary (ACS 50448) as an interim Compliance Officer of the Company with effect from December 07, 2019 for monitoring compliance with securities laws and redressal of investor grievances and any other ancillary activities.

7-Dec-19

Company has informed that Mr. Jayant Prakash, Compliance Officer, Company Secretary and Head of Legal (Key Managerial Personnel) has tendered his resignation from the Company and he will be relieved from his duties with the effect from December 6, 2019. Consequent to his resignation, he also ceases to be the Compliance Officer of the Company from the said date and also will be relieved from his duties.

29-Nov-19

Company has informed that Mr. Rakesh Agarwal has been appointed as Chief Financial Officer (CFO) of the Company with effect from November 11, 2019. Brief Profile of Mr. Rakesh Agarwal is given in Annexure-A herunder. Mr. Tushar Manohar Karnik, Current Chief Financial Officer of the Company has given notice of resignation from the services of the Company on account of personal reason which has been accepted by the Board in its Board Meeting held on November 11, 2019. His relieving is under process.

11-Nov-19

Company has informed that Desai Metropolis Health Services Private Limited, a wholly owned subsidiary of the Company, has acquired 4 (four) Laboratories from: (i) Doctor's Clinical Laboratory (partnership firm), (ii) Iyer Pathology Laboratory (sole proprietary), (iii) Nagar Pathology Laboratory (sole proprietary) and (iv) Yash Clinical Laboratory (sole proprietary), for providing diagnostic and pathological testing services in Surat, Gujarat.

30-Sep-19

Source: Stock Exchange filings